Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults. Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines.

The global Pneumonia Vaccine market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Pneumonia Vaccine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Pneumonia Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Pneumonia Vaccine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Pneumococcal Conjugate Vaccine (PCV13)
Pneumococcal Polysaccharide Vaccine (PPSV23)

Segment by Application
Pneumonia
Meningitis
Sepsis

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Pfizer Inc.
Glaxosmithkline Plc.
Merck & Co., Inc.
Sanofi Pasteur
Serum Institute of India Pvt. Ltd.
Johnson & Johnson
Astellas Pharma Inc.
Astrazeneca Plc.
CSL Limited
Emergent Biosolutions